NanoViricides, Inc.
NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage biotechnology company developing antiviral drugs based on its nanoviricide platform, which is designed to mimic host-cell features and bind to and disrupt virus particles. Its lead candidate, NV-387, is an oral broad-spectrum antiviral being developed for infections… From the company’s description.
In fiscal 2026, NanoViricides, Inc. reported a net loss of $8.22M. Operations used $7.70M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What NanoViricides, Inc. does
In the company’s own words
NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage biotechnology company developing antiviral drugs based on its nanoviricide platform, which is designed to mimic host-cell features and bind to and disrupt virus particles. Its lead candidate, NV-387, is an oral broad-spectrum antiviral being developed for infections including mpox, Ebola, measles and respiratory viruses; other programs target herpesviruses, HIV, dengue and additional viral diseases. The company has no customers, marketed products or revenue to date. Its pipeline spans clinical and preclinical development, and it also operates facilities for drug discovery, development, analytical testing and cGMP-compatible manufacturing of drug substances and products. NanoViricides licenses platform intellectual property from TheraCour Pharma and has out-licensed NV-CoV-2 development and commercialization in India to Karveer Meditech. For fiscal 2026, the company reports no revenue. Its website is http://www.Nanoviricides.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SHELTON, CT
- Fiscal year end
- June
- CIK
- 1379006
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NanoViricides, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NanoViricides, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NanoViricides, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NanoViricides, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NanoViricides, Inc.'s last four quarterly filings that the numbers alone won't show?”